ENTRY       D11833                      Drug
NAME        Glofitamab (USAN/INN);
            Glofitamab-gxbm;
            Columvi (TN)
PRODUCT     COLUMVI (Genentech)
FORMULA     C8632H13326N2296O2701S58
EXACT_MASS  194221.9788
MOL_WEIGHT  194341.7034
REMARK      Product: D11833<US>
EFFICACY    Antineoplastic
  DISEASE   Diffuse large B-cell lymphoma, not otherwise specified [DS:H02434]
            Follicular lymphoma [DS:H01613]
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      CD20 [HSA:931] [KO:K06466]
            CD3E [HSA:916] [KO:K06451]
  PATHWAY   hsa04640(916+931)  Hematopoietic cell lineage
BRITE       USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Glofitamab
                D11833  Glofitamab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D11833  Glofitamab (USAN/INN) &lt;US&gt;
                CD20
                 D11833  Glofitamab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11833
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11833
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11833
DBLINKS     CAS: 2229047-91-8
///
